School, of Psychological Sciences and Health, University of Strathclyde, Glasgow, UK.
Latin American Institute for Brain Health (BrainLat), Universidad Adolfo Ibanez, Santiago, Chile.
Alzheimers Dement. 2023 Feb;19(2):721-735. doi: 10.1002/alz.12757. Epub 2022 Sep 13.
Limited knowledge on dementia biomarkers in Latin American and Caribbean (LAC) countries remains a serious barrier. Here, we reported a survey to explore the ongoing work, needs, interests, potential barriers, and opportunities for future studies related to biomarkers. The results show that neuroimaging is the most used biomarker (73%), followed by genetic studies (40%), peripheral fluids biomarkers (31%), and cerebrospinal fluid biomarkers (29%). Regarding barriers in LAC, lack of funding appears to undermine the implementation of biomarkers in clinical or research settings, followed by insufficient infrastructure and training. The survey revealed that despite the above barriers, the region holds a great potential to advance dementia biomarkers research. Considering the unique contributions that LAC could make to this growing field, we highlight the urgent need to expand biomarker research. These insights allowed us to propose an action plan that addresses the recommendations for a biomarker framework recently proposed by regional experts.
拉丁美洲和加勒比(LAC)国家对痴呆症生物标志物的了解有限,这仍然是一个严重的障碍。在这里,我们报告了一项调查,以探讨与生物标志物相关的当前工作、需求、兴趣、潜在障碍和未来研究的机会。结果表明,神经影像学是使用最多的生物标志物(73%),其次是遗传研究(40%)、外周液生物标志物(31%)和脑脊液生物标志物(29%)。关于 LAC 的障碍,缺乏资金似乎破坏了生物标志物在临床或研究环境中的实施,其次是基础设施和培训不足。调查显示,尽管存在上述障碍,但该地区在推进痴呆症生物标志物研究方面具有巨大潜力。考虑到 LAC 可以为这个不断发展的领域做出的独特贡献,我们强调迫切需要扩大生物标志物研究。这些见解使我们能够提出一个行动计划,该计划针对最近由区域专家提出的生物标志物框架的建议。